HK1106723A1 - 抗日本腦炎病毒及西尼羅病毒的疫苗 - Google Patents

抗日本腦炎病毒及西尼羅病毒的疫苗

Info

Publication number
HK1106723A1
HK1106723A1 HK08100487.2A HK08100487A HK1106723A1 HK 1106723 A1 HK1106723 A1 HK 1106723A1 HK 08100487 A HK08100487 A HK 08100487A HK 1106723 A1 HK1106723 A1 HK 1106723A1
Authority
HK
Hong Kong
Prior art keywords
virus
west nile
japanese encephalitis
vaccines against
against japanese
Prior art date
Application number
HK08100487.2A
Other languages
English (en)
Inventor
Farshad Guirakhoo
Jian Liu
John A Catalan
Thomas P Monath
Konstantin V Pugachev
Original Assignee
賽諾菲巴斯德生物製藥有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 賽諾菲巴斯德生物製藥有限責任公司 filed Critical 賽諾菲巴斯德生物製藥有限責任公司
Publication of HK1106723A1 publication Critical patent/HK1106723A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
HK08100487.2A 2004-10-20 2008-01-15 抗日本腦炎病毒及西尼羅病毒的疫苗 HK1106723A1 (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US62046604P 2004-10-20 2004-10-20
US62094804P 2004-10-21 2004-10-21
US67441505P 2005-04-24 2005-04-24
US67454605P 2005-04-25 2005-04-25
US71892305P 2005-09-19 2005-09-19
PCT/US2005/037369 WO2006044857A2 (en) 2004-10-20 2005-10-19 Vaccines against japanese encephalitis virus and west nile virus

Publications (1)

Publication Number Publication Date
HK1106723A1 true HK1106723A1 (zh) 2008-03-20

Family

ID=36203650

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08100487.2A HK1106723A1 (zh) 2004-10-20 2008-01-15 抗日本腦炎病毒及西尼羅病毒的疫苗

Country Status (14)

Country Link
US (2) US8029802B2 (zh)
EP (1) EP1809325B1 (zh)
JP (1) JP4993301B2 (zh)
KR (1) KR101501162B1 (zh)
AU (1) AU2005295438B2 (zh)
CA (1) CA2584228C (zh)
EA (1) EA015907B1 (zh)
HK (1) HK1106723A1 (zh)
IL (1) IL182453A0 (zh)
MY (1) MY148075A (zh)
NO (1) NO20071924L (zh)
NZ (1) NZ584079A (zh)
SG (1) SG156666A1 (zh)
WO (1) WO2006044857A2 (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2439724T3 (es) 2001-06-01 2014-01-24 Sanofi Pasteur Biologics, Llc Vectores de flavivirus quiméricos
US7459160B2 (en) 2002-01-15 2008-12-02 Acambis Inc. Chimeric flaviviruses
EP1575979B1 (en) 2002-11-15 2009-12-23 Sanofi Pasteur Biologics Co. West nile virus vaccine
JP4993301B2 (ja) 2004-10-20 2012-08-08 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン
ES2478303T3 (es) 2005-04-24 2014-07-21 Sanofi Pasteur Biologics, Llc Vacunas de flavivirus recombinantes
AU2013204985B2 (en) * 2005-04-24 2016-01-28 Sanofi Pasteur Biologics, Llc Recombinant flavivirus vaccines
AU2008302276B2 (en) 2006-09-29 2013-10-10 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
SG174845A1 (en) 2006-09-29 2011-10-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
EP2851087B1 (en) 2006-11-07 2017-04-19 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
US8591916B2 (en) * 2007-01-31 2013-11-26 Sanofi Pasteur Biologics, Llc Flavivirus vaccine vector against influenza virus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
AU2009241354B2 (en) * 2008-04-30 2014-06-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric West Nile/Dengue viruses
DK2324113T3 (en) 2008-08-08 2018-04-16 Takeda Vaccines Inc VIRUS-LIKE PARTICLES INCLUDING COMPOSITE CAPSID AMINO ACID SEQUENCES FOR INCREASED CRYSTAL REACTIVITY
EP2358733B1 (en) * 2008-11-17 2015-07-08 Inovio Pharmaceuticals, Inc. Antigens that elicit immune response against flavivirus and methods of using same
WO2010141386A1 (en) 2009-06-01 2010-12-09 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
EP2459709B1 (en) 2009-07-31 2014-09-03 GE Healthcare Bio-Sciences Corp. High yield yellow fever virus strain with increased propagation in cells
WO2011119716A2 (en) * 2010-03-24 2011-09-29 Research Development Foundation Flavivirus host range mutations and uses thereof
CN101926989A (zh) * 2010-06-29 2010-12-29 西北农林科技大学 表达jev免疫原基因的重组减毒鼠伤寒沙门氏菌载体疫苗及其制备方法
WO2012003320A2 (en) * 2010-07-01 2012-01-05 Research Development Foundation Flavivirus host-range mutations and uses thereof
WO2013009849A1 (en) 2011-07-11 2013-01-17 Ligocyte Pharmaceuticals, Inc. Parenteral norovirus vaccine formulations
US9267114B2 (en) * 2012-11-07 2016-02-23 Southern Research Institute Flavivirus envelope protein mutations affecting virion disassembly
WO2014093182A1 (en) 2012-12-14 2014-06-19 Inviragen, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
WO2014204892A1 (en) 2013-06-21 2014-12-24 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
KR20160027019A (ko) * 2013-06-26 2016-03-09 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 뎅기 바이러스 백신에 대한 방법 및 조성물
WO2016079560A1 (en) 2014-11-21 2016-05-26 Institut Pasteur A live and attenuated japanese encephalitis virus comprising a mutated m protein
CR20170280A (es) 2014-12-22 2017-08-21 Merck Sharp & Dohme Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas
CA3209607A1 (en) * 2015-07-16 2017-01-19 Bharat Biotech International Limited Vaccine compositions
EP3947655A1 (en) * 2019-03-28 2022-02-09 Institut Pasteur A live and attenuated flavivirus comprising a mutated m protein

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173418A (en) 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US6676936B1 (en) 1988-07-14 2004-01-13 The United States Of America As Represented By The Department Of Health And Human Services. Chimeric and/or growth-restricted flaviviruses
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
JP4504464B2 (ja) * 1997-02-28 2010-07-14 サノフィ パスツール バイオロジクス カンパニー キメラフラビウイルスワクチン
US6589533B1 (en) 1997-09-18 2003-07-08 Research Development Foundation Genetically-engineered alphaviruses, flaviviruses, and bunyaviruses with modified envelope transmembrane glycoproteins and altered host-range phenotype
DE69833002T2 (de) 1997-10-08 2006-08-24 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Chimärer impfstoff gegen das zeckenenzephalitis virus
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
AU1813901A (en) 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
WO2002081753A1 (en) 2001-04-04 2002-10-17 Advanced Research & Technology Institute Method for identifying and characterizing individual dna molecules
US7459160B2 (en) 2002-01-15 2008-12-02 Acambis Inc. Chimeric flaviviruses
AU2003205169A1 (en) 2002-01-15 2003-07-30 Acambis, Inc. Viral vaccine production method
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
EP1575979B1 (en) 2002-11-15 2009-12-23 Sanofi Pasteur Biologics Co. West nile virus vaccine
US7189403B2 (en) * 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
JP4993301B2 (ja) 2004-10-20 2012-08-08 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン
ES2478303T3 (es) 2005-04-24 2014-07-21 Sanofi Pasteur Biologics, Llc Vacunas de flavivirus recombinantes

Also Published As

Publication number Publication date
EP1809325A4 (en) 2009-07-22
IL182453A0 (en) 2007-07-24
WO2006044857A2 (en) 2006-04-27
JP4993301B2 (ja) 2012-08-08
KR20070072597A (ko) 2007-07-04
AU2005295438B2 (en) 2012-07-05
US20070269458A1 (en) 2007-11-22
EP1809325B1 (en) 2013-11-20
EA200700904A1 (ru) 2007-12-28
CA2584228A1 (en) 2006-04-27
KR101501162B1 (ko) 2015-03-16
CA2584228C (en) 2015-05-05
US8691550B2 (en) 2014-04-08
SG156666A1 (en) 2009-11-26
NZ584079A (en) 2011-10-28
US20120201852A1 (en) 2012-08-09
EP1809325A2 (en) 2007-07-25
NO20071924L (no) 2007-07-17
US8029802B2 (en) 2011-10-04
WO2006044857A3 (en) 2006-08-10
MY148075A (en) 2013-02-28
JP2008520187A (ja) 2008-06-19
AU2005295438A1 (en) 2006-04-27
EA015907B1 (ru) 2011-12-30

Similar Documents

Publication Publication Date Title
IL182453A0 (en) Vaccines against japanese encephalitis virus and west nile virus
EP1804831A4 (en) VACCINES BASED ON LLO AND LISTERIA
IL179874A0 (en) Antibodies against west nile virus and therapeutic and prophylactic uses thereof
PL1673460T3 (pl) Szczepionki rekombinowane i ich zastosowanie
IL177667A0 (en) Flavivirus vaccines
EP1773384A4 (en) GENETICALLY MODIFIED SWINE INFLUENZA VIRUSES AND USES THEREOF
IL181477A0 (en) Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof
AU2003239932A8 (en) Tetravalent dengue vaccines
IL179545A (en) Viral and viral associated mirnas and uses thereof
GB0708705D0 (en) Improved vaccines
IL189329A (en) The vaccine against dengue fever virus infection has been used and used
ZA200703313B (en) Recombinant human T2 RNase and uses thereof
GB2435590B (en) An interleaver and associated methods
EP1773386A4 (en) VACCINE COMPOSITIONS AND CORRESPONDING METHODS
IL179373A0 (en) Treatment with irinotecan (cpt-11) and an egfr-inhibitor
EP1789554A4 (en) RECOMBINANT VACCINES AGAINST CALIGIDE COPEPODES (SEEDS) AND ANTIGEN SEQUENCES THEREOF
EP1814393A4 (en) TOLEROGENIC VACCINE AND METHOD THEREOF
EP1743680A4 (en) GAME SOFTWARE AND GAME DEVICE
AU2003206862A8 (en) Hepatitis b vaccines
GB0420634D0 (en) Vaccines
HK1109069A1 (en) Vaccine composition against hepatitis c virus
AU2003229474A8 (en) Methods and compositions for detecting sars virus
ZA200704033B (en) Vaccines against Japanese encephalitis virus and west nile virus
GB0406389D0 (en) Recombinant herpes simplex virus and uses therefor
GB0423681D0 (en) Vaccine and nucleic acids